Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 4/20 | 0.46 |
| ▸ | CCR2 | P41597 | 1/20 | 0.36 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.36 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.32 |
| ▸ | HTR1A | P08908 | 1/20 | 0.32 |
| ▸ | DRD3 | P35462 | 1/20 | 0.32 |
| ▸ | HTR2B | P41595 | 1/20 | 0.32 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.31 |
| ▸ | PIK3R1 | P27986 | 1/20 | 0.31 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.31 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.31 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16000539 | 0.83 | HRH3 (0.53) | HRH3CCR2KCNH2CHRM2HTR1A | |
| SCHEMBL16000538 | 0.83 | HRH3 (0.53) | HRH3CCR2KCNH2CHRM2HTR1A | |
| SCHEMBL12122183 | 0.83 | HRH3 (0.53) | HRH3CCR2KCNH2CHRM2HTR1A | |
| SCHEMBL20744643 | 0.78 | SLC6A2 (0.37) | HRH3PIK3CDPIK3R1PIK3CAPIK3CB | |
| SCHEMBL24139725 | 0.78 | HRH3 (0.51) | HRH3CCR2KCNH2CHRM2HTR1A | |
| SCHEMBL104879 | 0.78 | HRH3 (0.51) | HRH3CCR2KCNH2CHRM2HTR1A | |
| SCHEMBL10169535 | 0.76 | HRH3 (0.57) | HRH3CCR2KCNH2CHRM2HTR1A | |
| SCHEMBL20744158 | 0.75 | HRH3 (0.39) | HRH3CCR2KCNH2DRD3 | |
| SCHEMBL12110187 | 0.74 | HRH3 (0.46) | HRH3CCR2KCNH2CHRM2HTR1A | |
| SCHEMBL16000558 | 0.74 | HRH3 (0.51) | HRH3CCR2KCNH2CHRM2HTR1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11773058-B2 | Sulfonamide carboxamide compounds | INFLAZOME LIMITED (IE) | 2023-10-03 | — | — | US | disclosed |
| US-11773058-B2 | Sulfonamide carboxamide compounds | INFLAZOME LIMITED (IE) | 2023-10-03 | — | — | US | disclosed |
| US-11773058-B2 | Sulfonamide carboxamide compounds | INFLAZOME LIMITED (IE) | 2023-10-03 | — | — | US | disclosed |
| US-20200331850-A1 | NOVEL SULFONAMIDE CARBOXAMIDE COMPOUNDS | INFLAZOME LIMITED (IE) | 2020-10-22 | — | — | US | disclosed |
| US-20200331850-A1 | NOVEL SULFONAMIDE CARBOXAMIDE COMPOUNDS | INFLAZOME LIMITED (IE) | 2020-10-22 | — | — | US | disclosed |
| EP-3668601-A1 | NOVEL SULFONAMIDE CARBOXAMIDE COMPOUNDS | Inflazome Limited (IE) | 2020-06-24 | — | — | EP | disclosed |
| CN-111107903-A | Novel sulfonamide carboxamide compounds | 英夫拉索姆有限公司 | 2020-05-05 | — | — | CN | disclosed |
| WO-2019034696-A1 | NOVEL SULFONAMIDE CARBOXAMIDE COMPOUNDS | INFLAZOME LIMITED (IE) | 2019-02-21 | — | — | WO | disclosed |
| WO-2019034696-A1 | NOVEL SULFONAMIDE CARBOXAMIDE COMPOUNDS | INFLAZOME LIMITED (IE) | 2019-02-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11773058-B2 | Sulfonamide carboxamide compounds | NLRP3, NOD1, NLRP1 | HRH3 499/4885CCR2 686/4885KCNH2 784/4885 |
| US-20200331850-A1 | NOVEL SULFONAMIDE CARBOXAMIDE COMPOUNDS | NLRP3, NOD1, NLRP1 | HRH3 639/4885CCR2 699/4885KCNH2 815/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.